Astefania / WO42633

Topic of Study: Breast Cancer

Sponsor: F. Hoffmann-La Roche Ltd.

Principal Investigator: David Riseberg, M.D., 410-783-5858

Research Coordinator: Alexandra Cline, RN, 410-951-7956; Meeghan Bey, RN, 410-951-7908

Coordinated Through: Institutional Research

This global Phase 3, randomized, double blind study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant Atezolizumab when given in combination with trastuzumab emtansine compared with placebo and trastuzumab emtansine for patients with residual invasive HER2-positive breast cancer following neoadjuvant taxane-based and HER2-targeted therapy including trastuzumab, who are at high risk of disease recurrence. (Clinicaltrials.gov ID#: NCT04873362)